An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer

BACKGROUND: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negative breast cancer (TNBC) with intact DNA repair,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Stringer-Reasor, Erica M., May, Jori E., Olariu, Eva, Caterinicchia, Valerie, Li, Yufeng, Chen, Dongquan, Della Manna, Deborah L., Rocque, Gabrielle B., Vaklavas, Christos, Falkson, Carla I., Nabell, Lisle M., Acosta, Edward P., Forero-Torres, Andres, Yang, Eddy S.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934554/
https://ncbi.nlm.nih.gov/pubmed/33663560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-021-01408-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados